Shares of Abbott Laboratories advanced 3.74% to $131.35 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.33% to 5,693.31 and Dow ...

We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

Abbott Laboratories closed 11.07% short of its 52-week high of $141.23, which the company achieved on March 4th.

Thursday announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib).

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...